In an extensive bioinformatic investigation evaluating baseline antiviral resistance, researchers have discovered that drug resistance mutations and vaccine escape variants occur across global hepatitis B virus lineages, showing marked variation depending on viral genotype. Published in Frontiers in Microbiology, the investigation led by Gnanesvari Anandasaravanan, Sarah Sepehriamin, Johan Ringlander, Navaneethan Palanisamy, and Johan Lennerstrand evaluated more than seventeen thousand publicly available patient-derived viral sequences to map pre-existing resistance profiles against approved standards of care and investigational therapies. While antiviral treatments suppress viral replication in patients with chronic hepatitis B, a functional cure remains uncommon, achieved by only two to eleven percent of individuals receiving nucleos(t)ide analogs and approximately three to seven percent of those undergoing pegylated interferon-alpha therapy after one year. As novel therapeutic classes advance through clinical pipelines to target different stages of the viral lifecycle, understanding baseline mutant frequencies is essential for predicting efficacy, preventing treatment failure, and guiding clinical selection.
Chronic infection with hepatitis B virus represents a persistent worldwide health challenge, affecting approximately two hundred and fifty million people globally, including twelve percent who are children, and causing more than one million annual deaths primarily through hepatocellular cancer. The prevalence of chronic infection displays stark regional disparities, reaching five point eight percent across the African region and five percent in the Western Pacific region, compared to zero point five percent in the Americas. A central obstacle in eradicating the infection is the persistence of the covalently closed circular DNA pool inside host hepatocytes, maintained through cellular reinfection and intracellular nucleocapsid recycling. This nuclear reservoir displays an extended half-life and remains largely unaffected even through years of continuous antiviral administration. While older nucleos(t)ide analogs such as lamivudine, adefovir, and telbivudine were discontinued because viral resistance emerged readily, first-line therapies such as entecavir and tenofovir maintain substantially higher genetic barriers to resistance.
To overcome therapeutic limitations and target the viral lifecycle beyond reverse transcription, investigational drug platforms have entered clinical development. The entry inhibitor bulevirtide targets the sodium taurocholate co-transporting polypeptide receptor on hepatocytes, preventing viral attachment, limiting viral spread throughout hepatic tissue, and decreasing inflammation. Monoclonal antibodies such as tobevibart and brelovitug neutralize the surface antigen and inhibit viral engagement with cellular receptors. In post-entry stages, capsid assembly modulators such as bersacapavir alter capsid integrity by hyper-stabilizing the structure during uncoating or disrupting assembly after viral genome expression, thereby hindering covalently closed circular DNA formation. Furthermore, therapeutic platforms utilizing RNA interference, such as the small interfering RNA elebsiran, specifically target viral transcripts produced from viral mini-chromosomes or integrated DNA fragments, including precore, pregenomic, surface, and X messenger RNAs. However, early laboratory evidence demonstrates that specific amino acid substitutions and nucleotide alterations confer resistance to these emerging compounds, underscoring the need to benchmark their global natural occurrence.
To establish an evidence base for baseline mutation frequencies, the research team systematically extracted nineteen thousand one hundred and ninety-two unique sequence identifiers from the National Center for Biotechnology Information Nucleotide and Virus databases through October 2025. Following the manual exclusion of non-human isolates, ancient specimens, engineered constructs, and patent sequences, seventeen thousand two hundred and seventy-eight isolates remained, of which seventeen thousand and twelve were successfully genotyped. The team classified sequences utilizing the hepatitis B virus database genotyping tool and the Stanford University HBVseq sequence analysis tool, supplementing unresolved isolates with GenBank annotations. Genotypes C, B, D, and A predominated, jointly constituting approximately eighty-five percent of the dataset, mirroring global epidemiological patterns. Genotype-specific alignments were constructed using MAFFT version seven with default automated parameters and processed through AliView version one point thirty. Custom scripts developed in Python version 3.14.0 with Biopython 1.86 screened the reverse transcriptase, core, surface, and X regions for predefined resistance mutations identified from literature searches across PubMed and Google Search.
Analysis of the reverse transcriptase region demonstrated that classical nucleos(t)ide analog resistance variants were concentrated within specific genotypes. The primary resistance mutation M204I reached its highest frequency in genotype G, detected in thirteen point one percent of sequences, representing eleven out of eighty-four isolates. The dual compensatory combination L180M plus M204V was prominent across multiple lineages, occurring in sixteen point twenty-eight percent of recombinant AG sequences, twelve point sixty-four percent of genotype A sequences, and eleven point thirty-six percent of genotype H sequences. Overall entecavir-associated resistance was most frequent in recombinant AG at sixteen point twenty-eight percent, followed by genotype H at fifteen point ninety-one percent and genotype A at twelve point sixty-nine percent. Mechanistically, mutations in the catalytic tyrosine-methionine-aspartate-aspartate motif impair nucleos(t)ide binding efficiency, while secondary substitutions restore enzymatic fitness. Conversely, mutations conferring resistance to tenofovir, such as N236T and A181V, were observed only at very low frequencies, corroborating the exceptionally high genetic barrier characteristic of tenofovir.
In the core protein, which serves as the therapeutic target for capsid assembly modulators, overall resistance-associated variants appeared at lower frequencies than reverse transcriptase mutations, consistent with the lack of widespread clinical exposure to capsid-targeting drugs. Across the dataset, the core substitution Y38F was the most prevalent variant, reaching its peak frequency of eleven point six percent within recombinant DE isolates, comprising twenty-one out of one hundred and eighty-one sequences. Residue thirty-eight resides in a flexible, high-plasticity region of the capsid dimer interface under low conservation pressure. Other observed core mutations included T109M and I105T, which alter capsid stability and modulate inhibitor binding within the hydrophobic pocket. Several core substitutions previously associated with resistance in experimental settings—specifically F18A, P25G, R28A, T33G, T33Q, I105W, F110I, and V124F—were completely absent across all examined patient sequences. Among individual investigational modulators, BAY41-4109 resistance mutations peaked in genotype F at five point ninety-six percent, while Bersacapavir resistance appeared in two point sixty-three percent of recombinant AD sequences.
Evaluation of the surface antigen revealed that mutations reducing monoclonal antibody affinity or conferring vaccine escape occurred at low to moderate frequencies globally, with noticeable enrichment in specific viral subtypes. The benchmark vaccine escape substitution G145R was identified in only one point one percent of all analyzed sequences overall, but reached six point ninety-four percent in genotype I, accounting for seventeen of two hundred and forty-five isolates. Recombinant AG displayed the highest prevalence of the E164D substitution at nine point three percent, while E164G appeared predominantly in genotypes A and E. Monoclonal antibody resistance profiles exhibited marked variation: approximately seven percent of genotype I sequences harbored resistance mutations against both brelovitug and tobevibart, while nine percent of recombinant AG sequences carried variants conferring resistance to lenvervimab. In contrast, only four percent of genotype A sequences possessed lenvervimab resistance substitutions, and three point fifty-seven percent of genotype G isolates carried concurrent mutations reducing susceptibility across all three investigated monoclonal antibodies.
A critical finding from the surface antigen investigation was that several substitutions previously classified in the literature as vaccine escape mutations appear to be natural, genotype-specific polymorphisms rather than acquired immune-evasion variants. The substitutions S17A and P32L were detected in virtually all examined sequences, including near-universal prevalence in genotype C, despite earlier reports labeling them as escape mutants for that lineage. Similarly, the I110L substitution was identified in ninety-six point eighty-six percent of genotype C sequences, while appearing in only zero point eighty-five percent of genotype A sequences. Because universal vaccination programs remain highly effective in regions where genotype C predominates, the researchers emphasized that such widely distributed variants likely reflect baseline ancestral genetic architecture. Conversely, clinically verified escape mutations within the immunogenic a-determinant epitope between residues one hundred and twenty-four and one hundred and forty-seven occurred at very low rates overall, including P120S in zero point five percent, P120T in one point zero one percent, and D144A in zero point seventeen percent of sequences.
Because RNA interference agents and antisense oligonucleotides target nucleic acid sequences rather than translated proteins, the researchers analyzed the X open reading frame at the nucleotide level. Mutations associated with resistance to the small interfering RNA elebsiran were uncommon overall, reflecting strict evolutionary constraints imposed by the viral X protein, which plays an indispensable role in degrading the host structural maintenance of chromosomes five and six complex to facilitate viral transcription. The nucleotide substitution C13A was the most commonly detected resistance variant, ranging in frequency from zero to two point forty-four percent across genotypes and reaching its maximum in recombinant AD sequences. The C11T substitution varied between zero and two point forty-one percent, peaking in genotype G. When examining overall resistance to elebsiran across genotypes of interest, notable frequencies remained restricted to recombinant AD at four point eighty-eight percent, genotype G at two point forty-one percent, genotype A at one point eleven percent, and genotype C at zero point five percent.
The study authors highlighted several methodological limitations inherent to analyzing secondary public repositories that should contextualize these findings. First, public GenBank records generally lacked clinical metadata distinguishing treatment-experienced individuals from treatment-naive patients, precluding definitive conclusions regarding whether observed reverse transcriptase mutations arose spontaneously or were selected by previous entecavir therapy. Second, the dataset included multiple clonal sequences isolated from individual patients across time points, which could skew local frequency calculations due to viral quasi-species dynamics. Third, sample sizes varied substantially among genotypes: while genotypes C, B, D, and A dominated the dataset, rarer lineages and recombinant forms were represented by relatively few isolates, meaning estimates for underrepresented groups are less robust. Finally, the descriptive computational analysis did not evaluate phenotypic viral fitness in laboratory culture assays. Nevertheless, the investigators concluded that baseline resistance and vaccine escape mutations are established globally in circulating strains, demonstrating that routine genotypic resistance profiling prior to initiating emerging functional cure therapies will be vital to optimize long-term clinical outcomes.
Subject of Research: Frequency and genotype distribution of drug resistance and vaccine escape mutations in hepatitis B virus
Article Title: Frequency of hepatitis B virus mutations associated with resistance to current and emerging drugs for functional cure in publicly available hepatitis B virus sequences
Article References: Anandasaravanan, G., Sepehriamin, S., Ringlander, J., Palanisamy, N., & Lennerstrand, J. (2026). Frequency of hepatitis B virus mutations associated with resistance to current and emerging drugs for functional cure in publicly available hepatitis B virus sequences. Frontiers in Microbiology, 17, Article 2003253. https://doi.org/10.3389/fmicb.2026.2003253
Image Credits: AI Generated
DOI: 10.3389/fmicb.2026.2003253
Keywords: hepatitis B virus, chronic hepatitis B, antiviral drug resistance, vaccine escape mutations, functional cure, reverse transcriptase, core protein, surface antigen, X protein, entecavir, tenofovir, capsid assembly modulators, monoclonal antibodies, elebsiran, viral genotyping, HBV genotypes, cccDNA
News Source: Kristina Jarvis. (November 20, 2026). Hepatitis B Drug Resistance Mutations Found Across Global Sequence Lineages. Scienmag.



